Ignite Creation Date:
2024-05-05 @ 11:54 PM
Last Modification Date:
2024-10-26 @ 10:41 AM
Study NCT ID:
NCT01441388
Status:
WITHDRAWN
Last Update Posted:
2011-12-20
First Post:
2011-09-23
Brief Title:
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 1B Open-Label Dose Escalation Study To Evaluate Safety Pharmacokinetics And Pharmacodynamics Of Crizotinib PF-02341066 Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors
Status:
WITHDRAWN
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
BusinessOperational issues
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Despite the success of anti-angiogenic therapy in multiple treatment settings a fraction of patients are refractory to vascular endothelial growth factor VEGF inhibitor treatment while the majority of patients will eventually develop evasive resistance and exhibit disease progression while on therapy It is proposed that mesenchymal-epithelial transition factor c-MET and its ligand hepatocyte growth factor HGF or scatter factor contribute significantly to VEGF inhibitor resistance such that combining a c-MET inhibitor with a VEGF inhibitor will provide additional clinical activity compared to VEGF inhibitor alone This hypothesis will be tested using the cMETALK inhibitor crizotinib in combination with individual VEGF inhibitors Three combinations will be prioritized namely crizotinib plus axitinib crizotinib plus sunitinib and crizotinib plus bevacizumab with a fourth combination crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib andor sunitinib
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None